High dose oral ibuprofen in PDA closure in premature infants
Not Applicable
- Conditions
- Patent Ductus Arteriosus.Patent ductus arteriosus
- Registration Number
- IRCT201205029611N1
- Lead Sponsor
- Dean Of Research Of Shiraz University Of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
preterm infants with less than 37 weeks gestation and postnatal age of 3 to 7 days who will admitted at the neonatal intensive care unit of Shiraz Namazi and Hafez hospitals with clinical patent ductus arteriosus which was diagnosed by a pediatric cardiologist by using of Doppler echocardiography
exclusion criteria includes:major congenital anomalies; congenital heart defect; persistent pulmonary hypertension;life-threatening infections; sever bleeding; decreased Urine output<1 cc/kg/hr; impaired renal function with a serum(Cr<1.8 mg/dl); platelet count<50000; hematuria; gastrointestinal bleeding
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Closure of patent ductus arteriosus by echocardiography. Timepoint: 3rd day of birth(before intervention) and 7th day of birth(after intervention). Method of measurement: Doppler echocardiography was performed with a MindrayDC-7 echocardiography machine.
- Secondary Outcome Measures
Name Time Method Side effects like: decrease urine out put, gastrointestinal bleeding, impaired renal function, bleeding tendency and other drug's side effect. Timepoint: Daily clinical and laboratory evaluation before intervention till three days after intervention. Method of measurement: clinical evaluation and performing CBC,Cr, platlet, urine out put measurement.